Chinese clinicians report the case of a 73-year-old patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) who underwent treatment with a latest-generation immunosuppressant:
- the patient met all the criteria necessary to confirm the diagnosis of LEMS, including the onset of motor disorders in the context of small cell lung cancer, a compatible electrophysiological study and positive autoantibodies against VGCC and SOX-1.
- as corticosteroid therapy had failed, the patient was placed on efgartigimod, an immunotherapy already used in other neuromuscular junction disorders, such as autoimmune myasthenia gravis,
- the short- to medium-term results on motor disorders were very encouraging.
Although anecdotal, this observation could be useful for other cases of LEMS that respond poorly to current treatment protocols for this autoimmune disorder.
